Literature DB >> 25273296

The usefulness for indicated prevention of severe mental disorders should play a central part in the further development of CBT.

Joachim Klosterkötter1.   

Abstract

Entities:  

Year:  2014        PMID： 25273296      PMCID： PMC4219064          DOI： 10.1002/wps.20163

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  10 in total

1.  Preventing progression to first-episode psychosis in early initial prodromal states.

Authors:  A Bechdolf; M Wagner; S Ruhrmann; S Harrigan; V Putzfeld; R Pukrop; A Brockhaus-Dumke; J Berning; B Janssen; P Decker; R Bottlender; K Maurer; H-J Möller; W Gaebel; H Häfner; W Maier; J Klosterkötter
Journal:  Br J Psychiatry       Date:  2011-11-10       Impact factor: 9.319

2.  Prediction and prevention of schizophrenia: what has been achieved and where to go next?

Authors:  Joachim Klosterkötter; Frauke Schultze-Lutter; Andreas Bechdolf; Stephan Ruhrmann
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

3.  Salience and psychosis: moving from theory to practise.

Authors:  J Jensen; S Kapur
Journal:  Psychol Med       Date:  2008-08-12       Impact factor: 7.723

Review 4.  Measuring the global burden of disease.

Authors:  Christopher J L Murray; Alan D Lopez
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

Review 5.  Schizophrenia aetiology: do gene-environment interactions hold the key?

Authors: 
Journal:  Schizophr Res       Date:  2008-07       Impact factor: 4.939

6.  The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments.

Authors:  Michael E Thase; David Kingdon; Douglas Turkington
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

7.  Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.

Authors:  Andreas Bechdolf; Hendrik Müller; Hartmut Stützer; Michael Wagner; Wolfgang Maier; Marion Lautenschlager; Andreas Heinz; Walter de Millas; Birgit Janssen; Wolfgang Gaebel; Tanja Maria Michel; Frank Schneider; Martin Lambert; Dieter Naber; Martin Brüne; Seza Krüger-Özgürdal; Thomas Wobrock; Michael Riedel; Joachim Klosterkötter
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

Review 8.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

9.  The predictive validity of bipolar at-risk (prodromal) criteria in help-seeking adolescents and young adults: a prospective study.

Authors:  Andreas Bechdolf; Aswin Ratheesh; Sue M Cotton; Barnaby Nelson; Andrew M Chanen; Jennifer Betts; Tiffany Bingmann; Alison R Yung; Michael Berk; Patrick D McGorry
Journal:  Bipolar Disord       Date:  2014-05-05       Impact factor: 6.744

10.  Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial.

Authors:  Mark van der Gaag; Dorien H Nieman; Judith Rietdijk; Sara Dragt; Helga K Ising; Rianne M C Klaassen; Maarten Koeter; Pim Cuijpers; Lex Wunderink; Don H Linszen
Journal:  Schizophr Bull       Date:  2012-09-01       Impact factor: 9.306
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.